Compare LNTH & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LNTH | HALO |
|---|---|---|
| Founded | 1956 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 8.8B |
| IPO Year | 2014 | 2001 |
| Metric | LNTH | HALO |
|---|---|---|
| Price | $94.21 | $67.21 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 11 |
| Target Price | ★ $87.00 | $78.64 |
| AVG Volume (30 Days) | 795.5K | ★ 1.5M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.80 | 1.22 |
| Revenue | ★ $343,374,000.00 | $151,862,000.00 |
| Revenue This Year | N/A | $28.24 |
| Revenue Next Year | $14.19 | $12.56 |
| P/E Ratio | ★ $53.62 | $56.77 |
| Revenue Growth | ★ 3.62 | N/A |
| 52 Week Low | $47.27 | $51.06 |
| 52 Week High | $98.27 | $82.22 |
| Indicator | LNTH | HALO |
|---|---|---|
| Relative Strength Index (RSI) | 67.50 | 52.10 |
| Support Level | $72.35 | $62.53 |
| Resistance Level | N/A | $70.93 |
| Average True Range (ATR) | 3.21 | 2.67 |
| MACD | 0.76 | 0.43 |
| Stochastic Oscillator | 77.00 | 42.57 |
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.